FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients ages 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
